J. Goldman & Co’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

J. Goldman & Co’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-52,000	Closed	-$2.68M	–	395
2019 Q1	$2.68M	Sell	52,000 -52,000	-50%	-$2.25M	0.15%	151
2018 Q4	$3.85M	Buy	104,000 +39,000	+60%	+$1.41M	0.3%	100
2018 Q3	$2.44M	Sell	65,000 -54,000	-45%	-$1.99M	0.17%	144
2018 Q2	$4.7M	Buy	+119,000	New	+$3.78M	0.24%	132
2018 Q1	–	Sell	-74,300	Closed	-$2M	–	509
2017 Q4	$2M	Buy	+74,300	New	+$2.05M	0.11%	185

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Goldman & Co's BHVN Position: Q4 2021 in Review

J. Goldman & Co sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2021, closing a stake of 20,096 shares — an estimated $2.79M sold.

J. Goldman & Co first reported a position in BHVN in Q4 2017 and held it in 8 quarters. The position peaked at $2.88M in Q1 2018. 284 funds tracked by Wall St. Rank hold BHVN as of Q4 2021.

J. Goldman & Co reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2021 after selling out during the quarter.
J. Goldman & Co sold 20,096 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2021, an estimated $2.79M.
J. Goldman & Co first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 8 quarters.
J. Goldman & Co's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2.88M in Q1 2018.
284 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.